MA45141B1 - Procédé de préparation de n-(5-(3-(7-(3-fluorophényl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-méthylbutanamide - Google Patents

Procédé de préparation de n-(5-(3-(7-(3-fluorophényl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-méthylbutanamide

Info

Publication number
MA45141B1
MA45141B1 MA45141A MA45141A MA45141B1 MA 45141 B1 MA45141 B1 MA 45141B1 MA 45141 A MA45141 A MA 45141A MA 45141 A MA45141 A MA 45141A MA 45141 B1 MA45141 B1 MA 45141B1
Authority
MA
Morocco
Prior art keywords
pyridin
preparation
methylbutanamide
indazol
imidazo
Prior art date
Application number
MA45141A
Other languages
English (en)
Other versions
MA45141A (fr
Inventor
Sunil Kumar Kc
Original Assignee
Biosplice Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosplice Therapeutics Inc filed Critical Biosplice Therapeutics Inc
Priority claimed from PCT/US2017/035411 external-priority patent/WO2017210407A1/fr
Publication of MA45141A publication Critical patent/MA45141A/fr
Publication of MA45141B1 publication Critical patent/MA45141B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé synthétique de préparation d'un composé de formule (1). L'invention concerne également des intermédiaires et des sels utiles, des formes amorphes et polymorphes du composé de formule (1). Ces composés sont utiles contre diverses maladies, notamment le cancer, la prolifération cellulaire anormale, l'angiogenèse, la maladie d'alzheimer et l'ostéoarthrite, ainsi que les maladies liées à wnt.
MA45141A 2016-06-01 2017-06-01 Procédé de préparation de n-(5-(3-(7-(3-fluorophényl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-méthylbutanamide MA45141B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344170P 2016-06-01 2016-06-01
PCT/US2017/035411 WO2017210407A1 (fr) 2016-06-01 2017-06-01 Procédé de préparation de n-(5-(3-(7-(3-fluorophényl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-méthylbutanamide

Publications (2)

Publication Number Publication Date
MA45141A MA45141A (fr) 2019-04-10
MA45141B1 true MA45141B1 (fr) 2022-12-30

Family

ID=84783663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45141A MA45141B1 (fr) 2016-06-01 2017-06-01 Procédé de préparation de n-(5-(3-(7-(3-fluorophényl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-méthylbutanamide

Country Status (1)

Country Link
MA (1) MA45141B1 (fr)

Also Published As

Publication number Publication date
MA45141A (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
MX390577B (es) Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida.
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
BR112017013382A2 (pt) método para preparar um composto, composto, e, ácido.
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
MY200629A (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
WO2009091374A3 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX353461B (es) PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR).
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
WO2007058832A3 (fr) INHIBITEURS DES KINASES Tec
WO2015095337A3 (fr) Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs
WO2012044727A3 (fr) Procédé de fabrication de dérivés de pyrimidine
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
WO2008024151A3 (fr) Sels et co-cristaux de composés de pyrazolopyrimidine, leurs compositions, et procédés de production et d'utilisation
WO2014014794A3 (fr) Antagonistes des récepteurs aux minéralocorticoïdes
WO2008101029A3 (fr) Procédés d'utilisation de composés de thiazole, d'oxazole et d'imidazole dans le traitement de maladies ou d'états provoqués par le canal sodique
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner